POSIFLEX-TECHNOLOGY
Posiflex Technology Inc., a global leader in Point of Sale (POS) systems and Online to Offline (O2O) solutions, is pleased to announce its latest flagship POS terminal series – Mozart BT. The Mozart BT Series introduces beautiful modular monitor systems that integrate high-performance computing power, the latest operating system, and user-friendly ergonomic designs. With a high degree of modularity in construction and sleek elegance in appearance, the series conceals all cables and connectors, perfectly integrating the printer, providing a sense of space economy and aesthetics that enhances Posiflex's brand identity. The small and clean footprint of the Mozart BT Series allows seamless integration into various commercial spaces such as fashion boutiques, hospitality, convenience stores, food and beverage establishments, or multifunctional storefronts. Designed for versatility, it is an ideal solution for businesses requiring an additional display on the counter board for advertising playback, offering an elegant, beautiful, and useful POS terminal solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240714496907/en/
Posiflex Mozart BT Series POS Terminals (Photo: Business Wire)
A Harmonious Work of Paper-Thin Elegance
Posiflex's Mozart BT Series, aptly named, strives to unite all its structural, functional, and aesthetic elements into a seamless harmony, reminiscent of a Symphony composition. Following the design principle of "less is more," the thinner display, host, and stand, along with narrower monitor bezels, not only reduce the system's size and weight but also enhance its functionality. Every curve and angle is meticulously crafted to convey a sense of elegance. Integrated and concealed designs ensure the elimination of exposed cables and connectors, presenting a clean and uncluttered aesthetic. The overall outcome is a sleek, harmonious, and elegant masterpiece.
Ripple Brand Identity
The ripple icon on the start button and thermal printer gives a sense of brand identity, symbolizing the continued vitality and the continuous quest for innovation and user benefit. The burgundy red on the sides of the stand suggests understated luxury and the deep, round taste associated with red wine.
Brilliant Modularity
Modular design has consistently been the pinnacle of innovation in Posiflex products, and the Mozart BT Series has elevated modularity to new heights. Each main component, from displays to the host and thermal printer, is independent, facilitating easy installation, removal for repair and maintenance, yet seamlessly integrates in function and structure when assembled into the system. The thermal printer is cleverly incorporated into the stand, becoming an integral part of the POS terminal base. Alternatively, it can function independently, showcasing a design that optimizes both space and functionality ingeniously.
User-Friendly Ergonomic Designs
The Mozart BT Series POS terminal incorporates ergonomic designs to optimize the user experience. Narrow bezels on the displays minimize interference with the user's view, directing attention to the screen. Moreover, the adjustable angles of the displays cater to the user's comfort and dynamic needs. Both main and secondary displays can be vertically oriented, aligning with current market trends. Additionally, all peripherals are positioned at the same level from the user's perspective, promoting heightened comfort.
State-of-the-Art Specifications
The Mozart BT Series POS Terminal stands out with a host of impressive features. It runs on the latest operating systems, including Android 13 with EDLA certified (GMS) or Windows 11 OS, available in both x86 and RISC variants. The terminal is powered by up to the latest 13th-generation Intel processor, ensuring top-notch performance. Users can choose between a 15" or 15.6" LCD display, notably the 15.6" main screen featuring oTP technology (typical 400 nits) for vibrant colors and high brightness. Plus, the terminal offers versatility with accessory and attachment choices, including the 3-in-1 side attachment for RFID/MSR/FPU, iButton, 2D BCR (discrete/side attached), and the detachable printer.
These features combine to provide a powerful and versatile electronic POS system with high-speed processing power and the ability to run the latest applications to meet the changing needs of the retail and hospitality industry.
About POSIFLEX Group
Posiflex Group is a global leading Commercial AIoT platform powered by smart Online-to-Offline (O2O) and Scenario-defined Embedded Appliance Solutions. Pillared by three brands, Posiflex Group consists of Posiflex as global top 5 brand in POS & Kiosk, Portwell as Embedded Foundry for AIoT Edge Compute, and KIOSK Information Systems (KIS) for managed self-service automation – together with a common mission to enable optimized productivity and superior customer journey across the connected world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240714496907/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom